Clinical Trial Detail

NCT ID NCT03662659
Title An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Bristol-Myers Squibb
Indications

stomach cancer

gastroesophageal junction adenocarcinoma

Therapies

Nivolumab + Relatlimab + Tegafur-gimeracil-oteracil Potassium

Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin + Relatlimab

Nivolumab + Tegafur-gimeracil-oteracil Potassium

Capecitabine + Nivolumab + Oxaliplatin

Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin

Capecitabine + Nivolumab + Oxaliplatin + Relatlimab

Age Groups: adult senior

Additional content available in CKB BOOST